Hjem › Akut myelogen leukemi › California › Sacramento
Kliniske studier for Akut myelogen leukemi i Sacramento, CA
12 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Sacramento (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruttererFase 2
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
RekruttererFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Mercy Cancer Center - Sacramento, Sacramento
- Woodland Memorial Hospital, Woodland · 16 mi unna
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RekruttererFase 1
- UC Davis, Sacramento
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekruttererFase 3
- University of California Davis Comprehensive Cancer Center, Sacramento
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
RekruttererFase 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservasjonsstudie
- Sutter Medical Center, Sacramento
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
RekruttererFase 2
- University of California Davis Health (UC Davis Health), Sacramento
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RekruttererFase 1/2
- University of California, Davis, Sacramento
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RekruttererFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Akut myelogen leukemi-studier i andre byer
- Houston, TX85 studier
- New York City, NY51 studier
- Boston, MA44 studier
- Seattle, WA41 studier
- Baldwin Park, CA40 studier
- Columbus, OH35 studier
- Philadelphia, PA34 studier
- Durham, NC33 studier
- Atlanta, GA31 studier
- Tampa, FL29 studier
- Chicago, IL26 studier
- Portland, OR25 studier
Andre studier i Sacramento
- Ikke-småcellet lungekreft29 studier
- Lungekreft22 studier
- Brystkreft20 studier
- Prostatakreft19 studier
- Metastatisk kreft16 studier
- Hjertesvikt12 studier
- Pankreaskreft12 studier
- Kreft (alle typer)11 studier
- Tykktarmskreft11 studier
- Blærekreft10 studier
- Kolorektal kreft10 studier
- Type 2-diabetes9 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.